GlassScriptPhysician profile
Luis A Bolanos
NPI 1285687673
$1,111.63
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $121 · 2021: $181 · 2022: $143 · 2023: $355 · 2024: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $312.68 | 2019-2024 | Vaxelis, Gardasil 9, M-M-R II |
| Ironshore Pharmaceuticals INC. | $120.98 | 2019-2020 | |
| Pfizer INC. | $104.71 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.30 | 2020-2021 | |
| Glaxosmithkline, LLC. | $96.04 | 2019-2023 | Bexsero |
| Cranial Technologies, INC | $93.90 | 2020-2023 | Doc Band |
| Sanofi Pasteur INC. | $84.01 | 2020-2023 | |
| Adlon Therapeutics L.P. | $62.40 | 2020-2021 | |
| Hologic Sales and Service, LLC | $35.77 | 2023 | Aptima |
| Seqirus USA INC | $23.46 | 2024 | Flucelvax |
| Sobi, INC | $21.40 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.83 | 2024 | Qelbree |
| Biomarin Pharmaceutical INC. | $18.07 | 2022 | |
| Phadia US INC. | $16.08 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Bolanos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.